Loading
IMPDH1 (Inosine-5'-monophosphate dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 2 more.
Catalyses the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumours.
Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.94, animal model 0.50, genetic association 0.00, clinical 0.91).
In plain words · IMPDH1 (Inosine-5'-monophosphate dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 2 more.
IMPDH1 (Inosine-5'-monophosphate dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 2 more.
Catalyses the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth.
No product in this corpus aims at IMPDH1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA IMPDH1: RNA tissue enhanced (retina 99 nTPM); blood lineage group enriched (dendritic cells 60 nTPM, granulocytes 198 nTPM, monocytes 137 nTPM); high antibody staining in 1 normal tissue; highest cancer staining lymphoma (2 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute lymphoblastic leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas IMPDH1 tissue; Open Targets ENSG00000106348 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Natsumeda et al, J. Biol. Chem, 1990, "Two distinct cDNAs for human IMP dehydrogenase". Source.
Sources: HGNC HGNC:6052 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P20839 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000106348 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.53, acute lymphoblastic leukaemia 0.53, non-Hodgkin lymphoma 0.54, myeloproliferative neoplasm 0.53, leukaemia 0.56 (GraphQL API, CC0))
Catalyses the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumours. Location: Cytoplasm; Nucleus (UniProt). Locus 7q32.1 (HGNC).
RNA: tissue enhanced (retina 99 nTPM), detected in all normal tissues. Blood: group enriched (dendritic cells 60 nTPM, granulocytes 198 nTPM, monocytes 137 nTPM).
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA IMPDH1 tissue · HPA IMPDH1 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IMPDH1" OR ABSTRACT:"IMPDH1" OR TITLE:"inosine monophosphate dehydrogenase 1" OR ABSTRACT:"inosine monophosphate dehydrogenase 1" OR TITLE:"Inosine-5'-monophosphate dehydrogenase 1" OR ABSTRACT:"Inosine-5'-monophosphate dehydrogenase 1" OR TITLE:"sWSS2608" OR ABSTRACT:"sWSS2608" OR TITLE:"LCA11" OR ABSTRACT:"LCA11" OR TITLE:"RP10" OR ABSTRACT:"RP10") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IMPDH1, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.